Finerenone reduces Incidence of Heart Failure in Diabetics with Kidney Disease

被引：0
|
作者：
Franke, Katharina
机构：
来源：
AKTUELLE KARDIOLOGIE | 2022年 / 11卷 / 03期
关键词：
D O I：
10.1055/a-1826-4716
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Der im Februar 2022 in Europa zugelassene selektive nichtsteroidale Mineralokortikoid-Rezeptor-Antagonist Finerenon hat gunstige Auswirkungen auf kardiorenale Endpunkte, wie vor Kurzem in der FIDELIO-DKD und in der FIGARO-DKD-Studie gezeigt werden konnte. Eine praspezifizierte Post-hoc-Analyse der FIGARO-DKD-Studie ergab jetzt insbesondere auch protektive Wirkungen der Substanz im Hinblick auf verschiedene Herzinsuffizienz-Endpunkte.
引用
收藏
页码：200 / 200
页数：1
相关论文
共 50 条
  • [1] Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes
    Filippatos, Gerasimos
    Anker, Stefan D.
    Pitt, Bertram
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Lambelet, Marc
    Lawatscheck, Robert
    Bakris, George L.
    Ruilope, Luis M.
    Agarwal, Rajiv
    JACC-HEART FAILURE, 2022, 10 (11) : 860 - 870
  • [2] Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
    Pradhan, Akshyaya
    Tripathi, Umesh Chandra
    EGYPTIAN HEART JOURNAL, 2024, 76 (01):
  • [3] Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure
    Memon, Ayesha Abdul Qadir
    Iqbal, Sarmad
    GLOBAL JOURNAL OF MEDICAL PHARMACEUTICAL AND BIOMEDICAL UPDATE, 2022, 17 (12): : 1 - 8
  • [4] Is It Primetime for Finerenone in Heart Failure?
    Dixit, Neal M.
    Schaefer, Saul
    CIRCULATION-HEART FAILURE, 2025, 18 (01)
  • [5] Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
    Filippatos, Gerasimos
    Anker, Stefan D.
    Agarwal, Rajiv
    Ruilope, Luis M.
    Rossing, Peter
    Bakris, George L.
    Tasto, Christoph
    Joseph, Amer
    Kolkhof, Peter
    Lage, Andrea
    Pitt, Bertram
    CIRCULATION, 2022, 145 (06) : 437 - 447
  • [6] Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
    Liu, Licette C. Y.
    Schutte, Elise
    Gansevoort, Ron T.
    van der Meer, Peter
    Voors, Adriaan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (08) : 1123 - 1135
  • [7] Finerenone and Kidney Outcomes in Patients With Heart Failure The FINEARTS-HF Trial
    Mc Causland, Finnian R.
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Kulac, Ian J.
    Desai, Akshay S.
    Jhund, Pardeep S.
    Henderson, Alasdair D.
    Brinker, Meike
    Perkins, Robert
    Scheerer, Markus F.
    Schloemer, Patrick
    Lam, Carolyn S. P.
    Senni, Michele
    Shah, Sanjiv J.
    Voors, Adriaan A.
    Zannad, Faiez
    Pitt, Bertram
    Mcmurray, John J. V.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (02) : 159 - 168
  • [8] Finerenone in chronic kidney disease
    Susan J. Allison
    Nature Reviews Nephrology, 2021, 17 : 13 - 13
  • [9] Finerenone in chronic kidney disease
    Allison, Susan J.
    NATURE REVIEWS NEPHROLOGY, 2021, 17 (01) : 13 - 13
  • [10] FINERENONE Mineralocorticoid receptor (MR) antagonist Treatment of chronic kidney disease/diabetic nephropathy Treatment of heart failure
    Cole, P.
    DRUGS OF THE FUTURE, 2015, 40 (12) : 801 - 808
12345